Dupilumab for cancer-associated refractory pruritus

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Malignancy-associated pruritus (MAP) is a debilitating symptom driven by Type 2 inflammation, involving cytokines IL-4, IL-13, and IL-31.
• Dupilumab targets the IL-4 receptor alpha (IL-4Rα), inhibiting IL-4 and IL-13 signaling, which can reduce IL-31 production.

Purpose of the Study:

• To evaluate the safety and efficacy of dupilumab for treating refractory MAP in a small patient cohort.
• To establish a foundation for larger clinical trials investigating dupilumab in cancer patients with pruritus.

Main Methods:

• A case study involving three patients with intractable MAP secondary to prostate cancer, cutaneous T-cell lymphoma, and metastatic melanoma.
• Patients received biweekly dupilumab treatment after failing conventional antipruritic therapies and showing no signs of atopic dermatitis or other common pruritus causes.

Main Results:

• All three patients experienced rapid and complete resolution of itching after initiating dupilumab treatment.
• No significant adverse events were reported during the treatment period, indicating a favorable safety profile.

Conclusions:

• Dupilumab demonstrates potential as a safe and effective therapeutic option for patients suffering from intractable malignancy-associated pruritus.
• Further investigation in a larger patient cohort is warranted to confirm these preliminary findings.